The clinical relevance of humoral immune responses to Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 and expression of Globo H in metastatic breast cancer

An international randomized phase II trial of Globo H (GH) vaccine, adagloxad simolenin/OBI-821 in 349 patients with metastatic breast cancer showed longer progression-free survival (PFS) in vaccinated patients who developed anti-Globo H (anti-GH) IgG than those who did not and the placebo group. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Hung, Jung-Tung, Chen, I-Ju, Ueng, Shir-Hwa, Huang, Chiun-Sheng, Chen, Shin-Cheh, Chen, Mu-Yi, Lin, Yung-Chang, Lin, Chun-Yen, Campbell, Michael J, Rugo, Hope S, Yu, Alice L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9226869/
https://www.ncbi.nlm.nih.gov/pubmed/35732348
http://dx.doi.org/10.1136/jitc-2021-004312

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9226869/
https://www.ncbi.nlm.nih.gov/pubmed/35732348
http://dx.doi.org/10.1136/jitc-2021-004312

Ejemplares similares